Prolactinoma Clinical Trial
Official title:
Comparison of Exercise Capacity, Physical Activity Level and Quality of Life in Prolactinoma Patients and Healthy Individuals
Prolactinoma, one of the most common pituitary adenomas, is an adenoma that causes excessive prolactin (PRL) secretion. An increase in prolactin level can cause weakness, decrease in muscle mass and fatigue. It is not known in detail to what extent it affects quality of life, functional exercise capacity, cardiovascular disease risk factors, physical activity level, fatigue and sleep quality in prolactinoma patients. It is aimed to compare how much exercise capacity, physical activity level, sleep quality, perception of fatigue and quality of life of prolactinoma patients are affected compared to healthy individuals and to examine the factors associated with exercise capacity in prolactinoma patients.
Prolactinoma is a pituitary adenoma caused by excessive prolactin secretion. More than 70% of patients are women. Many physiological conditions such as pregnancy, breastfeeding, breast stimulation, stress, exercise and sleep can also increase PRL levels. Prolactin can affect arterial stiffness and blood pressure and cause atherosclerosis in early menopause. In addition to these, it has negative effects on heart rhythm and heart failure. In addition to these clinical findings, the extent to which body weight gain and fatigue symptoms affect quality of life, functional exercise capacity, cardiovascular disease risk factors, physical activity level, fatigue and sleep quality in prolactinoma patients is not known in detail. There are very few studies on these subjects. Height, weight, waist circumference, hip circumference will be measured for all participants, waist-hip ratio and body mass index (BMI) will be calculated. The exercise capacity levels of the individuals who will participate in the study will be evaluated with the 6 Minute Walk Test (6MWT). Risk factors knowledge levels about cardiovascular diseases will be evaluated with Cardiovascular Diseases Risk Factors Knowledge Level (CARRIF-BD) Scale. Physical activity level will be evaluated with the Turkish version of the short form of the International Physical Activity Questionnaire (IPAQ). The Pittsburgh Sleep Quality Index (PUKI) was used to evaluate sleep quality. Fatigue assessment will be evaluated with the Multidimensional Fatigue Rating Scale. quality of life will be evaluated with the SF-36 short form. Measurement of knee extensor muscle strength will be made with a portable digital dynamometer (JTECH, Medical Commander Powertrack II, Midvale, USA). Peripheral muscle endurance assessment will be done by bilateral squat test. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03038308 -
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03400865 -
Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas
|
N/A | |
Completed |
NCT00481299 -
Insulin Resistance in Women With Prolactinoma
|
N/A | |
Terminated |
NCT04106531 -
Validation of a Quality of Life Metric "Prolac-10"
|
||
Completed |
NCT01504399 -
Rhinological Outcomes in Endonasal Pituitary Surgery
|
||
Recruiting |
NCT03474601 -
Seoul National University Pituitary Disease Cohort Study
|
||
Recruiting |
NCT04107480 -
PRolaCT - Three Prolactinoma RCTs
|
Phase 4 | |
Completed |
NCT00697814 -
Clomiphene in Males With Prolactinomas and Persistent Hypogonadism
|
Phase 2 | |
Recruiting |
NCT03353025 -
Study on Therapy of Non-invasive Prolactinoma
|
N/A | |
Recruiting |
NCT03457389 -
Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma
|
N/A | |
Recruiting |
NCT01775332 -
Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
|
N/A | |
Not yet recruiting |
NCT03717454 -
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas
|
N/A | |
Recruiting |
NCT00001595 -
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
|